Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.

J. U. Gutterman, J. O. Cardenas, G. R. Blumenschein, G. Hortobagyi, M. A. Burgess, Robert B Livingston, G. M. Mavligit, E. J. Freireich, J. A. Gottlieb, Evan M Hersh

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73% and 76% for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (medium 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trial of chemoimmunotherapy of breast cancer should be carried out.

Original languageEnglish (US)
Pages (from-to)1222-1225
Number of pages4
JournalBMJ (Clinical research ed.)
Volume2
Issue number6046
StatePublished - Nov 20 1976
Externally publishedYes

Fingerprint

Mycobacterium bovis
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Survival
Combination Drug Therapy
Immunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gutterman, J. U., Cardenas, J. O., Blumenschein, G. R., Hortobagyi, G., Burgess, M. A., Livingston, R. B., ... Hersh, E. M. (1976). Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. BMJ (Clinical research ed.), 2(6046), 1222-1225.

Chemoimmunotherapy of advanced breast cancer : prolongation of remission and survival with BCG. / Gutterman, J. U.; Cardenas, J. O.; Blumenschein, G. R.; Hortobagyi, G.; Burgess, M. A.; Livingston, Robert B; Mavligit, G. M.; Freireich, E. J.; Gottlieb, J. A.; Hersh, Evan M.

In: BMJ (Clinical research ed.), Vol. 2, No. 6046, 20.11.1976, p. 1222-1225.

Research output: Contribution to journalArticle

Gutterman, JU, Cardenas, JO, Blumenschein, GR, Hortobagyi, G, Burgess, MA, Livingston, RB, Mavligit, GM, Freireich, EJ, Gottlieb, JA & Hersh, EM 1976, 'Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.', BMJ (Clinical research ed.), vol. 2, no. 6046, pp. 1222-1225.
Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB et al. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. BMJ (Clinical research ed.). 1976 Nov 20;2(6046):1222-1225.
Gutterman, J. U. ; Cardenas, J. O. ; Blumenschein, G. R. ; Hortobagyi, G. ; Burgess, M. A. ; Livingston, Robert B ; Mavligit, G. M. ; Freireich, E. J. ; Gottlieb, J. A. ; Hersh, Evan M. / Chemoimmunotherapy of advanced breast cancer : prolongation of remission and survival with BCG. In: BMJ (Clinical research ed.). 1976 ; Vol. 2, No. 6046. pp. 1222-1225.
@article{538fdeb4639b4075ba1fb5e0bfcad675,
title = "Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.",
abstract = "Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73{\%} and 76{\%} for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (medium 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trial of chemoimmunotherapy of breast cancer should be carried out.",
author = "Gutterman, {J. U.} and Cardenas, {J. O.} and Blumenschein, {G. R.} and G. Hortobagyi and Burgess, {M. A.} and Livingston, {Robert B} and Mavligit, {G. M.} and Freireich, {E. J.} and Gottlieb, {J. A.} and Hersh, {Evan M}",
year = "1976",
month = "11",
day = "20",
language = "English (US)",
volume = "2",
pages = "1222--1225",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6046",

}

TY - JOUR

T1 - Chemoimmunotherapy of advanced breast cancer

T2 - prolongation of remission and survival with BCG.

AU - Gutterman, J. U.

AU - Cardenas, J. O.

AU - Blumenschein, G. R.

AU - Hortobagyi, G.

AU - Burgess, M. A.

AU - Livingston, Robert B

AU - Mavligit, G. M.

AU - Freireich, E. J.

AU - Gottlieb, J. A.

AU - Hersh, Evan M

PY - 1976/11/20

Y1 - 1976/11/20

N2 - Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73% and 76% for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (medium 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trial of chemoimmunotherapy of breast cancer should be carried out.

AB - Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73% and 76% for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (medium 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trial of chemoimmunotherapy of breast cancer should be carried out.

UR - http://www.scopus.com/inward/record.url?scp=17144457942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144457942&partnerID=8YFLogxK

M3 - Article

C2 - 791447

AN - SCOPUS:17144457942

VL - 2

SP - 1222

EP - 1225

JO - The BMJ

JF - The BMJ

SN - 0959-8146

IS - 6046

ER -